Eric Gordon (Partner, Skyline Ventures)

-

Location: 184 Nieuwland Science Hall

"Career Paths: A Conversation with Dr. Eric Gordon, Scientist, Entrepreneur and Investor"
Dr. Eric Gordon received his PhD in chemistry from the University of Wisconsin-Madison and conducted postdoctoral research at Yale University. He spent 18 years at Squibb as a medicinal chemist rising to Director of Medicinal Chemistry, then moved to the biotech industry where he was Vice President of Research at Affymax, President and CSO at Versicor, and Senior Vice President of Research at Sunesis Pharmaceuticals. He has worked on rational drug design in numerous areas, including angiotensin converting enzyme inhibitors, rennin inhibition, aminopeptidases inhibitors, inhibition of bacterial cell wall biosynthesis, inhibition of beta-lactamases, cyclooxygenase and 5-lipooxygenase inhibitors, mammalian cholesterol biosynthesis, prenylated proteins, viral proteases, and kinases. He was involved in the discovery/development of 5 FDA-approved drugs (Captoten, Azactam, Pravachol, Fosfenopril, Omapatrilat). He was founding member of Versicor (a company focused on drug discovery of antibiotic drugs) and Sunesis Pharmaceuticals (a company focused on protein interfaces, enzymes, and small molecule-protein receptors), where he raised over $93 million in financing. He is the author of more than 200 scientific manuscripts and patents. He is on the editorial board of Journal of Combinatorial Chemistry , The Combinatorial Chemistry Journal , Current Opinion in Drug Discovery and Development, Current Opinion in Anti-infective Investigational Drugs, and the Journal of Medicinal Chemistry. In 1997, he was elected a Fellow of the American Association Advancement of Science. Since 2002, he has divided his time between being a partner at Skyline Ventures in Palo Alto, founding Tetraphase, and consulting for a number of biotech firms.